Multiple endocrine neoplasia type 2 cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 2}} | {{Multiple endocrine neoplasia type 2}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Cost- | Cost-effective management of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic [[thyroidectomy]] and restricted molecular screening. | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
===Methods for | ===Methods for Cost Effectiveness of the Therapy=== | ||
* Molecular screening of ''RET'' | * [[Molecular]] [[Screening (medicine)|screening]] of [[RET gene|''RET'' gene]] limiting to [[exon]] 10,11 and 16 is an effective way of reducing the cost of management of [[thyroidectomy]]. | ||
* For [[diagnosis]] of multiple endocrine neoplasia type 2B, investigation of [[exon]] 16 is adequate and this further is a cost effective method.<ref name="pmid19443294">{{cite journal| author=Chang CF, Yang WS, Su YN, Wu IL, Chang TC| title=Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan. | journal=J Formos Med Assoc | year= 2009 | volume= 108 | issue= 5 | pages= 402-8 | pmid=19443294 | doi=10.1016/S0929-6646(09)60084-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19443294 }} </ref> | * For [[diagnosis]] of multiple endocrine neoplasia type 2B, investigation of [[exon]] 16 is adequate and this further is a cost effective method.<ref name="pmid19443294">{{cite journal| author=Chang CF, Yang WS, Su YN, Wu IL, Chang TC| title=Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan. | journal=J Formos Med Assoc | year= 2009 | volume= 108 | issue= 5 | pages= 402-8 | pmid=19443294 | doi=10.1016/S0929-6646(09)60084-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19443294 }} </ref> | ||
* Prophylactic [[thyroidectomy]] of patients screened positive for ''RET'' | * [[Prophylactic]] [[thyroidectomy]] of patients screened positive for [[RET gene|''RET'' gene]] is a cost effective way of management of [[thyroidectomy]].<ref name="pmid11981210">{{cite journal| author=Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC et al.| title=Gastrointestinal manifestations of multiple endocrine neoplasia type 2. | journal=Ann Surg | year= 2002 | volume= 235 | issue= 5 | pages= 648-54; discussion 654-5 | pmid=11981210 | doi= | pmc=PMC1422490 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11981210 }} </ref> | ||
* Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.<ref name=Cost-effectiveness | * Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.<ref name="Cost-effectiveness">{{cite web | title = CREST Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B| url = http://www.crest.uts.edu.au/pdfs/MEN2B_final.pdf }}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Oncology]] | |||
[[Category:Diseases]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Up-To-Date]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 02:46, 27 November 2017
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
FDA on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
CDC on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
Multiple endocrine neoplasia type 2 cost-effectiveness of therapy in the news |
|
Blogs on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost-effective management of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic thyroidectomy and restricted molecular screening.
Cost-Effectiveness of Therapy
Methods for Cost Effectiveness of the Therapy
- Molecular screening of RET gene limiting to exon 10,11 and 16 is an effective way of reducing the cost of management of thyroidectomy.
- For diagnosis of multiple endocrine neoplasia type 2B, investigation of exon 16 is adequate and this further is a cost effective method.[1]
- Prophylactic thyroidectomy of patients screened positive for RET gene is a cost effective way of management of thyroidectomy.[2]
- Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.[3]
References
- ↑ Chang CF, Yang WS, Su YN, Wu IL, Chang TC (2009). "Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan". J Formos Med Assoc. 108 (5): 402–8. doi:10.1016/S0929-6646(09)60084-X. PMID 19443294.
- ↑ Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC; et al. (2002). "Gastrointestinal manifestations of multiple endocrine neoplasia type 2". Ann Surg. 235 (5): 648–54, discussion 654-5. PMC 1422490. PMID 11981210.
- ↑ "CREST Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B" (PDF).